Exercise in Therapy and Prevention of Type II Diabetes: Implications for Blacks

Department of Medicine, Boston University Medical Center, Massachusetts.
Diabetes Care (Impact Factor: 8.42). 12/1990; 13(11):1163-8. DOI: 10.2337/diacare.13.11.1163
Source: PubMed


The rationale for the use of exercise in the treatment of type II (non-insulin-dependent) diabetes and its special implications for Blacks are reviewed herein. When performed on a regular basis, exercise may improve glycemic control and improve several risk factors for coronary heart disease including hypertriglyceridemia, hypertension, and hyperinsulinemia. In addition, it may be a useful adjunct to diet in producing weight loss. The metabolic benefits of exercise in part appear to be related to its ability to enhance insulin sensitivity. Benefits are short lived after discontinuing exercise. Because of problems with compliance and concurrent medical problems, many patients with type II diabetes are not good candidates for an exercise-diet program. For this reason, the optimum target population may be people at risk for type II diabetes and premature atherosclerosis. Such a population might include the offspring of patients with these disorders and individuals with impaired glucose tolerance, hyperinsulinemia, gestational diabetes, and/or an android pattern of fat distribution. Type II diabetes is more common in Blacks than in the general population. In most instances, it is associated with cardiovascular risk factors benefited by exercise. Despite this, there are no available studies regarding the effects of regular exercise in Blacks with type II diabetes or those at risk for it.

Download full-text


Available from: Stephen Schneider, Oct 08, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Persons from ethnic minority populations in the United States suffer disproportionately more from type 2 diabetes and its complica- tions than do Caucasians. Genetic and ac- quired factors likely contribute to the ethnic disparities of type 2 diabetes. The pathophys- iologic hallmarks consist of insulin resistance, progressive pancreatic b-cell dysfunction, and excessive hepatic glucose production. The ideal treatment for type 2 diabetes should correct insulin resistance and b-cell dysfunc- tion; and normalize hepatic glucose output; and prevent, delay, or reverse diabetic com- plications. The discovery of a new class of drugs, thiazolidinediones, has provided an effective tool to correct key underlying defects in type 2 diabetes. Thiazolidinediones improve insulin sensitivity and have beneficial effects on pancreatic b-cell function and hepatic glucose production. Furthermore, their potent insulin-sensitization effect predicts that treat- ment with thiazolidinediones will improve cardiovascular risk factors, including lipid pro- file, fibrinolysis, endothelial function, and atheroinflammatory markers. These benefits are expected to be particularly important among ethnic minority patients who tend to have greater insulin resistance than do Cauca- sians. (Ethn Dis. 2006;16:51-57)
  • [Show abstract] [Hide abstract]
    ABSTRACT: More than 170 million people worldwide have diabetes, and the World Health Organization (WHO) projects that this number will more than double by the year 2030. Most of the increase is expected to occur in developing countries, where diabetes already affects people in their most productive years, the 45- to 64-yr age bracket (1). In the United States, an estimated 17.7 million people have diabetes, and this number is expected to increase to 30.3 million by 2030 (2). Thus, diabetes is poised to become one of the primary causes of disability and death worldwide within the next 25 yr. From these data, it is clear that there is an urgent need to develop and implement effective strategies to prevent diabetes. This chapter will review the evidence regarding predictors of diabetes and therapies to prevent diabetes, and will discuss how diabetes prevention strategies can be applied in the “real world.”
  • [Show abstract] [Hide abstract]
    ABSTRACT: The potential role of physical activity in the primary prevention of non-insulin-dependent diabetes mellitus (NIDDM) is largely unknown. We examined the association between regular vigorous exercise and the subsequent incidence of NIDDM in a prospective cohort of 87,253 US women aged 34-59 years and free of diagnosed diabetes, cardiovascular disease, and cancer in 1980. During 8 years of follow-up, we confirmed 1303 cases of NIDDM. Women who engaged in vigorous exercise at least once per week had an age-adjusted relative risk (RR) of NIDDM of 0.67 (p less than 0.0001) compared with women who did not exercise weekly. After adjustment for body-mass index, the reduction in risk was attenuated but remained statistically significant (RR = 0.84, p = 0.005). When analysis was restricted to the first 2 years after ascertainment of physical activity level and to symptomatic NIDDM as the outcome, age-adjusted RR of those who exercised was 0.5, and age and body-mass index adjusted RR was 0.69. Among women who exercised at least once per week, there was no clear dose-response gradient according to frequency of exercise. Family history of diabetes did not modify the effect of exercise, and risk reduction with exercise was evident among both obese and nonobese women. Multivariate adjustments for age, body-mass index, family history of diabetes, and other variables did not alter the reduced risk found with exercise. Our results indicate that physical activity may be a promising approach to the primary prevention of NIDDM.
    The Lancet 10/1991; 338(8770):774-8. DOI:10.1016/0140-6736(91)90664-B · 45.22 Impact Factor
Show more